Clearside Biomedical has raised $16m in a series B round featuring pharmaceutical company Santen and RusnanoMedInvest, for the development of treatments for blinding diseases of the eye.
US-based biopharmaceutical company Clearside Biomedical has raised $16m in series B funding from RusnanoMedInvest, a subsidiary of the state-run Russian investment firm Rusnano.
Japan-based Santen Pharmaceutical’s US subsidiary was also involved, alongside venture capital firms Hatteras Venture Partners, Mountain Group Capital and Georgia Research Alliance Venture Fund, a private investment fund created to help finance GRA Ventures, the commercialisation arm of the Georgia Research Alliance.
Clearside Biomedical develops drug therapies to treat blinding diseases of the eye. The funding will support drug development and the…
